Quidel Co. (NASDAQ:QDEL) Director Jack W. Schuler sold 4,000 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.60, for a total value of $178,400.00. Following the sale, the director now owns 3,365,553 shares of the company’s stock, valued at $150,103,663.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Quidel Co. (QDEL) traded down $0.18 during trading hours on Friday, reaching $45.99. The company’s stock had a trading volume of 95,300 shares, compared to its average volume of 343,786. The company has a market capitalization of $1,560.00, a price-to-earnings ratio of -287.44, a P/E/G ratio of 1.48 and a beta of 1.15. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70. Quidel Co. has a 1-year low of $18.25 and a 1-year high of $47.60.
Quidel (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.21). Quidel had a negative return on equity of 2.36% and a negative net margin of 2.33%. The firm had revenue of $50.89 million during the quarter, compared to the consensus estimate of $50.47 million. During the same quarter in the previous year, the company posted $0.10 EPS. The firm’s revenue was up 3.1% on a year-over-year basis. equities research analysts expect that Quidel Co. will post -0.23 earnings per share for the current year.
Several equities research analysts have recently weighed in on QDEL shares. Raymond James Financial reissued a “buy” rating and issued a $47.00 price target (up previously from $41.00) on shares of Quidel in a research note on Tuesday, September 19th. Piper Jaffray Companies raised Quidel from a “neutral” rating to an “overweight” rating and increased their price target for the company from $35.00 to $50.00 in a research note on Tuesday, September 19th. Zacks Investment Research raised Quidel from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $48.00 target price (up previously from $42.00) on shares of Quidel in a research note on Tuesday, September 19th. Finally, Barclays reaffirmed a “buy” rating and set a $45.00 target price (up previously from $39.00) on shares of Quidel in a research note on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Quidel currently has an average rating of “Buy” and a consensus target price of $50.00.
Several hedge funds have recently bought and sold shares of the company. Tandem Investment Advisors Inc. bought a new stake in Quidel during the fourth quarter worth $640,000. Wolverine Trading LLC bought a new stake in Quidel during the third quarter worth $406,000. California Public Employees Retirement System lifted its holdings in Quidel by 3.8% during the third quarter. California Public Employees Retirement System now owns 58,103 shares of the company’s stock worth $2,548,000 after acquiring an additional 2,103 shares during the period. Davidson Kempner Capital Management LP bought a new stake in Quidel during the third quarter worth $6,974,000. Finally, Jane Street Group LLC bought a new stake in Quidel during the third quarter worth $205,000. Institutional investors own 92.67% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Quidel Co. (QDEL) Director Sells 4,000 Shares of Stock” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/01/14/quidel-co-qdel-director-sells-178400-00-in-stock-updated-updated.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.